Share on StockTwits

NeoGenomics (NYSE:NEO) Director Michael T. Dent sold 300,000 shares of the company’s stock on the open market in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $3.00, for a total value of $900,000.00. Following the completion of the sale, the director now directly owns 437,500 shares of the company’s stock, valued at approximately $1,312,500. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

NeoGenomics (NYSE:NEO) traded up 0.55% during mid-day trading on Wednesday, hitting $5.45. 328,508 shares of the company’s stock traded hands. NeoGenomics has a 52-week low of $2.13 and a 52-week high of $5.77. The stock’s 50-day moving average is $5.09 and its 200-day moving average is $3.85. The company has a market cap of $273.4 million and a P/E ratio of 135.50.

NeoGenomics (NYSE:NEO) last posted its quarterly earnings results on Thursday, July 17th. The company reported $0.01 EPS for the quarter, meeting the Thomson Reuters consensus estimate of $0.01. The company had revenue of $20.70 million for the quarter, compared to the consensus estimate of $19.84 million. The company’s quarterly revenue was up 32.7% on a year-over-year basis. Analysts expect that NeoGenomics will post $0.01 EPS for the current fiscal year.

NeoGenomics, Inc (NYSE:NEO) operates a network of cancer-focused testing laboratories.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.